Cytokinetics (CYTK) Convertible Debt (2019 - 2025)
Historic Convertible Debt for Cytokinetics (CYTK) over the last 6 years, with Q3 2024 value amounting to $551.5 million.
- Cytokinetics' Convertible Debt rose 61.06% to $551.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $551.5 million, marking a year-over-year increase of 61.06%. This contributed to the annual value of $549.0 million for FY2023, which is 58.28% up from last year.
- According to the latest figures from Q3 2024, Cytokinetics' Convertible Debt is $551.5 million, which was up 61.06% from $550.6 million recorded in Q2 2024.
- Cytokinetics' 5-year Convertible Debt high stood at $551.5 million for Q3 2024, and its period low was $85.5 million during Q1 2020.
- Over the past 5 years, Cytokinetics' median Convertible Debt value was $134.7 million (recorded in 2022), while the average stood at $311.9 million.
- In the last 5 years, Cytokinetics' Convertible Debt soared by 48048.25% in 2022 and then skyrocketed by 57.76% in 2023.
- Over the past 5 years, Cytokinetics' Convertible Debt (Quarter) stood at $89.5 million in 2020, then increased by 6.67% to $95.5 million in 2021, then surged by 471.7% to $545.8 million in 2022, then increased by 0.58% to $549.0 million in 2023, then rose by 0.45% to $551.5 million in 2024.
- Its last three reported values are $551.5 million in Q3 2024, $550.6 million for Q2 2024, and $549.8 million during Q1 2024.